Schizophrenia Market

Schizophrenia is a severe mental illness, which interferes with a person’s ability to think, manage emotions, make decisions, and relate to others.

Although Schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early twenties for men and the late twenties to early thirties for women. It is uncommon for the disease to be diagnosed younger than 12 or older than 40. 

Schizophrenia is not caused by just one genetic variation but a complex interplay of genetics and environmental influences. While Schizophrenia occurs in one percent of the general population, having a history of family psychosis significantly increases the risk. Schizophrenia occurs in roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.

Schizophrenia Epidemiological Segmentation 

The Epidemiological Segmentation of Schizophrenia in 7MM from 2017 to 2030 is segmented as:- 

  • Prevalent Cases  
  • Diagnosed Prevalent cases
  • Gender-specific Diagnosed Prevalent cases
  • Age-specific Diagnosed Prevalent cases
  • Severity-specific Diagnosed Prevalent cases

Schizophrenia Epidemiology 

  • The total prevalent population of Schizophrenia in 7MM in 2017 was 5,616,463
  • EU5 countries occupied 22.47% of the patient pool amongst 7MM in 2017

Schizophrenia Market

The market size of Schizophrenia in 7MM in 2017 was USD 6,066.97 million

Schizophrenia Market Drivers

  • Increasing Awareness
  • Growing Research and development
  • Pipeline Advancement
  • Long-acting Injectable Antipsychotics

Schizophrenia Market Barriers

  • Economic Burden
  • Significant Side Effects of Approved Therapy
  • Denial of illness
  • Co-occurring medical conditions

Schizophrenia Emerging Drugs

The emerging drugs of the Schizophrenia market are 

  • Doria (risperidone ISM)
  • Roluperidone (MIN-101)
  • SEP-363856
  • Pimavanserin
  • Encenicline (EVP-6124
  • Dexmedetomidine (BXCL501)
  • Avisetron (AVN-211)
  • ALKS 3831 (Olanzapine + Samidorphan)
  • AVP-786
  • Lu AF11167
  • GWP42003 (Cannabidiol/GWP42003-P)
  • BI 409306
  • KarXT
  • TAK-831
  • NaBen (Sodium Benzoate)
  • BI 425809
  • BIIB104 (AMPA)
  • PF-06412562
  • CTP-692
  • Evenamide (NW-3509/NW-3509A)
  • Miricorilant
  • MK-8189
  • CPL500036

And many others.  

Schizophrenia Key Players

The key players in the Schizophrenia market are

  • Rovi Pharmaceuticals Laboratories
  • Minerva Neurosciences
  • Sunovion/PsychoGenics
  • Acadia Pharmaceuticals
  • Forum Pharmaceuticals
  • BioXcel Therapeutics
  • Avineuro Pharmaceuticals
  • Alkermes
  • Avanir Pharmaceuticals
  • Otsuka Pharmaceutical
  • H. Lundbeck A/S
  • GW Research
  • Boehringer Ingelheim
  • Karuna Pharmaceuticals
  • Takeda
  • SyneuRx International
  • Biogen
  • Cerevel Therapeutics
  • Pfizer
  • Concert Pharmaceuticals
  • Newron Pharmaceuticals
  • Merck
  • Celon Pharma

And many others.